Found: 112
Select item for more details and to access through your institution.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
- Published in:
- Hepatology Research, 2024, v. 54, n. 4, p. 382, doi. 10.1111/hepr.13991
- By:
- Publication type:
- Article
Geriatric nutritional risk index as an easy‐to‐use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
- Published in:
- Hepatology Research, 2023, v. 53, n. 10, p. 1031, doi. 10.1111/hepr.13934
- By:
- Publication type:
- Article
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
- Published in:
- Hepatology Research, 2023, v. 53, n. 8, p. 737, doi. 10.1111/hepr.13905
- By:
- Publication type:
- Article
Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.
- Published in:
- Hepatology Research, 2023, v. 53, n. 2, p. 172, doi. 10.1111/hepr.13845
- By:
- Publication type:
- Article
Clinical outcomes of antithrombin III‐based therapy for patients with portal vein thrombosis: A retrospective, multicenter study.
- Published in:
- Hepatology Research, 2023, v. 53, n. 1, p. 51, doi. 10.1111/hepr.13840
- By:
- Publication type:
- Article
Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib.
- Published in:
- Hepatology Research, 2022, v. 52, n. 12, p. 1050, doi. 10.1111/hepr.13824
- By:
- Publication type:
- Article
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice.
- Published in:
- Hepatology Research, 2022, v. 52, n. 9, p. 773, doi. 10.1111/hepr.13797
- By:
- Publication type:
- Article
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 5, p. 462, doi. 10.1111/hepr.13748
- By:
- Publication type:
- Article
Time‐course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 3, p. 235, doi. 10.1111/hepr.13739
- By:
- Publication type:
- Article
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 3, p. 308, doi. 10.1111/hepr.13734
- By:
- Publication type:
- Article
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study.
- Published in:
- Hepatology Research, 2021, v. 51, n. 12, p. 1229, doi. 10.1111/hepr.13718
- By:
- Publication type:
- Article
Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression.
- Published in:
- Hepatology Research, 2021, v. 51, n. 8, p. 880, doi. 10.1111/hepr.13644
- By:
- Publication type:
- Article
Histopathological analysis of autoimmune hepatitis with "acute" presentation: Differentiation from drug‐induced liver injury.
- Published in:
- Hepatology Research, 2020, v. 50, n. 9, p. 1047, doi. 10.1111/hepr.13532
- By:
- Publication type:
- Article
Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 209, doi. 10.1159/000527402
- By:
- Publication type:
- Article
What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 2, p. 115, doi. 10.1159/000513355
- By:
- Publication type:
- Article
EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis.
- Published in:
- Liver Cancer (2235-1795), 2020, v. 9, n. 6, p. 734, doi. 10.1159/000508971
- By:
- Publication type:
- Article
Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma.
- Published in:
- Gastroenterology Report, 2021, v. 9, n. 2, p. 133, doi. 10.1093/gastro/goaa042
- By:
- Publication type:
- Article
A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C.
- Published in:
- PLoS ONE, 2021, v. 16, n. 9, p. 1, doi. 10.1371/journal.pone.0257166
- By:
- Publication type:
- Article
Assessment of Ultra-Early-Stage Liver Fibrosis in Human Non-Alcoholic Fatty Liver Disease by Second-Harmonic Generation Microscopy.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 6, p. 3357, doi. 10.3390/ijms23063357
- By:
- Publication type:
- Article
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate‐stage hepatocellular carcinoma.
- Published in:
- Liver International, 2024, v. 44, n. 1, p. 113, doi. 10.1111/liv.15753
- By:
- Publication type:
- Article
Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
- Published in:
- Liver International, 2020, v. 40, n. 4, p. 968, doi. 10.1111/liv.14405
- By:
- Publication type:
- Article
Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study.
- Published in:
- Hepatology Research, 2020, v. 50, n. 5, p. 557, doi. 10.1111/hepr.13482
- By:
- Publication type:
- Article
Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching.
- Published in:
- Hepatology Research, 2020, v. 50, n. 1, p. 75, doi. 10.1111/hepr.13427
- By:
- Publication type:
- Article
Intention‐to‐treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world.
- Published in:
- Hepatology Research, 2019, v. 49, n. 12, p. 1365, doi. 10.1111/hepr.13410
- By:
- Publication type:
- Article
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan.
- Published in:
- Hepatology Research, 2019, v. 49, n. 4, p. 369, doi. 10.1111/hepr.13292
- By:
- Publication type:
- Article
Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis.
- Published in:
- Hepatology Research, 2019, v. 49, n. 1, p. 111, doi. 10.1111/hepr.13243
- By:
- Publication type:
- Article
Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator‐blinded, active‐controlled trial and a phase III, multicenter, open trial.
- Published in:
- Hepatology Research, 2018, v. 48, n. 6, p. 411, doi. 10.1111/hepr.13045
- By:
- Publication type:
- Article
Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy.
- Published in:
- Hepatology Research, 2017, v. 47, n. 12, p. 1308, doi. 10.1111/hepr.12898
- By:
- Publication type:
- Article
Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan.
- Published in:
- Hepatology Research, 2016, v. 46, n. 8, p. 734, doi. 10.1111/hepr.12613
- By:
- Publication type:
- Article
Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study.
- Published in:
- Hepatology Research, 2016, v. 46, n. 6, p. 521, doi. 10.1111/hepr.12583
- By:
- Publication type:
- Article
Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype.
- Published in:
- Hepatology Research, 2015, v. 45, n. 4, p. 387, doi. 10.1111/hepr.12360
- By:
- Publication type:
- Article
A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study.
- Published in:
- Hepatology Research, 2014, v. 44, n. 14, p. E386, doi. 10.1111/hepr.12323
- By:
- Publication type:
- Article
Usefulness of combined application of double-filtration plasmapheresis and twice-daily injections of interferon-β in hemodialysis patients with hepatitis C virus genotype 1b infection and a high viral load.
- Published in:
- Hepatology Research, 2014, v. 44, n. 10, p. E257, doi. 10.1111/hepr.12207
- By:
- Publication type:
- Article
Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma.
- Published in:
- Hepatology Research, 2014, v. 44, n. 3, p. 296, doi. 10.1111/hepr.12123
- By:
- Publication type:
- Article
Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
- Published in:
- Hepatology Research, 2014, v. 44, n. 1, p. 73, doi. 10.1111/hepr.12098
- By:
- Publication type:
- Article
Effects of branched-chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis.
- Published in:
- Hepatology Research, 2013, v. 43, n. 5, p. 459, doi. 10.1111/j.1872-034X.2012.01097.x
- By:
- Publication type:
- Article
Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C S. Kaneko et al. DFPP increases cEVR rates of interferon therapy.
- Published in:
- Hepatology Research, 2010, v. 40, n. 11, p. 1072, doi. 10.1111/j.1872-034X.2010.00708.x
- By:
- Publication type:
- Article
Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, n. 5, p. N.PAG, doi. 10.1093/ofid/ofz185
- By:
- Publication type:
- Article
Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment.
- Published in:
- Current Oncology, 2022, v. 29, n. 5, p. 3259, doi. 10.3390/curroncol29050266
- By:
- Publication type:
- Article
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
- Published in:
- Oncology, 2023, v. 101, n. 10, p. 624, doi. 10.1159/000531316
- By:
- Publication type:
- Article
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
- Published in:
- Oncology, 2023, v. 101, n. 9, p. 542, doi. 10.1159/000530028
- By:
- Publication type:
- Article
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
- Published in:
- Oncology, 2023, v. 101, n. 4, p. 270, doi. 10.1159/000527676
- By:
- Publication type:
- Article
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
- Published in:
- Oncology, 2022, v. 100, n. 12, p. 645, doi. 10.1159/000526521
- By:
- Publication type:
- Article
Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.
- Published in:
- Oncology, 2022, v. 100, n. 2, p. 65, doi. 10.1159/000520292
- By:
- Publication type:
- Article
Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
- Published in:
- Oncology, 2021, v. 99, n. 8, p. 518, doi. 10.1159/000515896
- By:
- Publication type:
- Article
Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
- Published in:
- Oncology, 2020, v. 98, n. 5, p. 295, doi. 10.1159/000506293
- By:
- Publication type:
- Article
Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.
- Published in:
- Oncology, 2019, v. 97, n. 6, p. 334, doi. 10.1159/000502095
- By:
- Publication type:
- Article
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
- Published in:
- Oncology, 2019, v. 97, n. 5, p. 277, doi. 10.1159/000501281
- By:
- Publication type:
- Article
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
- Published in:
- Cancer Reports, 2024, v. 7, n. 4, p. 1, doi. 10.1002/cnr2.2042
- By:
- Publication type:
- Article
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
- Published in:
- Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1464
- By:
- Publication type:
- Article